Search

Displaying results 3821 - 3830 of 9333 in total
  1. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. … In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.

  2. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression

  3. Drug

    Histamine

    go.drugbank.com/drugs/DB05381
    ApprovedInvestigational

    A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.

  4. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. … Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from _Mycobacterium bovis_, and the human papilloma viral (HPV) protein E7.

  5. Drug

    Opipramol

    go.drugbank.com/drugs/DB12930
    Investigational

    Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  7. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. … Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours.

  8. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

  9. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment … It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.

  10. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect … (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG).